The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life ...

Tom Wells at 4C Associates, explores the future of biologistics, or how the packaging, storage, and logistics for biologics ...

Strong IP keeps collaboration alive, allowing companies to attract capital, strike partnerships, and bring innovations to patients, according to legal experts at Ice Miller.

Leadership means knowing when to jump in and when to let someone else worry about the details, writes Hope Mueller, SVP of Corporate Development and Strategy at Currax Pharmaceuticals.

On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

Biopharma leaders are often celebrated for the breakthroughs their companies pursue, from the elegant science to the pioneering modalities and the once-impossible therapies edging closer to reality.

The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue ...

Marc Tessier-Lavigne, Ph.D. (left) and Martin Makary, M.D. (right) The FDA must “cut the idle time” that exists within the agency to bring drugs to market faster, said Commissioner Martin Makary, M.D.

As a CEO and a member of the Biotech CEO Sisterhood, I see a disconnect in our industry. Women are driving breakthrough innovations, leading successful companies through crisis, and delivering results ...

Navigating a serious diagnosis, chronic condition, or major treatment can be an isolating experience — for both patients and caregivers. Yet, across countless diseases and life challenges, many find ...

Clinical trials are built around time-sensitive, patient-centered moments, such as when a patient arrives for a visit or completes a key assessment. Yet too often, disconnected technologies and ...